Evidence mapPaperPMID 40272281Full record

ReviewDiabetes care2025

Youth-Onset Type 2 Diabetes: What We've Learned From Key Youth-Onset Type 2 Diabetes Studies, What We Still Don't Know, and Why It Is Important.

Kristen J Nadeau, Elizabeth J Mayer-Davis, Rose Gubitosi-Klug, Philip S Zeitler, Steven E Kahn, Dana Dabelea, SEARCH, TODAY, RISE, and DISCOVERY study groups

Abstract readReview
In one paragraph

Review in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kristen J NadeauPediatric Endocrinology, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-0477-3356
Elizabeth J Mayer-DavisDepartment of Nutrition and School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0003-3858-0517
Rose Gubitosi-KlugDivision of Pediatric Endocrinology and Metabolism, Case Western Reserve University and Rainbow Babies & Children's Hospital, Cleveland, OH.ORCID 0000-0002-7376-6870
Philip S ZeitlerPediatric Endocrinology, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Steven E KahnDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA.ORCID 0000-0001-7307-9002
Dana DabeleaLifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0001-9514-8929
SEARCH, TODAY, RISE, and DISCOVERY study groups

Funding

Statistics Center for Pediatric Type 2 Diabetes TherapyU01DK061230 · GEORGE WASHINGTON UNIVERSITY · 2001 to 2005
$69.5M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · 1986 to 2025
$12.6M
Yale Diabetes Research CenterP30DK045735 · YALE UNIVERSITY · 1993 to 2025
$10.2M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2025 to 2025
$10.1M
Yale Clinical and Translational Science AwardUL1TR001863 · YALE UNIVERSITY · 2025 to 2025
$9.9M
Southern California Clinical and Translational Science InstituteUL1TR001855 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$9.1M
Management of Pediatric Type 2 Diabetes MellitusU01DK061239 · CHILDRENS HOSPITAL OF PHILADELPHIA · 2001 to 2005
$4.6M
Multi-Center Study of the Treatment of T2DM in YouthU01DK061212 · YALE UNIVERSITY · 2001 to 2005
$3.9M
Type 2 Diabetes in Youth: Beta Cell PreservationU01DK061254 · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · 2001 to 2005
$3.6M
Treatment Alternatives in Pediatric Type 2 DiabetesU01DK061242 · UNIVERSITY OF COLORADO DENVER · 2001 to 2005
$3.5M
Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes - Biostatistics Research CenterU01DK134971 · GEORGE WASHINGTON UNIVERSITY · 2025 to 2025
$3.1M
Translation CoreP30DK097512 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$1.7M
Division of Diabetes, Endocrinology, and Metabolic DiseasesHSRD VA HIR 10-001NCATS NIH HHS TL1 TR001858NCATS NIH HHS UL1 TR000430NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1 TR001855NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001863NCCDPHP CDC HHS U01 DP000244NCCDPHP CDC HHS U01 DP000246NCCDPHP CDC HHS U01 DP000247NCCDPHP CDC HHS U01 DP000248NCCDPHP CDC HHS U01 DP000250NCCDPHP CDC HHS U01 DP000254NCCDPHP CDC HHS U18 DP002708NCCDPHP CDC HHS U18 DP002710NCCDPHP CDC HHS U18 DP002714NCCDPHP CDC HHS U18 DP006131NCCDPHP CDC HHS U18 DP006133NCCDPHP CDC HHS U18 DP006134NCCDPHP CDC HHS U18 DP006136NCCDPHP CDC HHS U18 DP006138NCCDPHP CDC HHS U18 DP006139NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020595NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK097512NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254NIDDK NIH HHS U01 DK094406NIDDK NIH HHS U01 DK094430NIDDK NIH HHS U01 DK094431NIDDK NIH HHS U01 DK094438NIDDK NIH HHS U01 DK094467NIDDK NIH HHS U01 DK134958NIDDK NIH HHS U01 DK134971NIDDK NIH HHS UC4 DK108173
6 · The paper itself

Abstract

In this review, we describe the epidemiology, pathophysiology, pediatric-specific treatment response data, morbidity, and mortality of youth-onset type 2 diabetes. In recognition of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 75th anniversary, the focus is primarily on data from three landmark youth-onset type 2 diabetes studies funded by the NIDDK in the last 20+ years. We discuss the now-recognized aggressive clinical course of youth-onset type 2 diabetes, which only recently became appreciated as a pediatric disease among health care providers. We highlight the similarities and differences between youth-onset and adult-onset type 2 diabetes, in particular how type 2 diabetes in youth appears to have an accelerated clinical course with earlier onset of complications in comparison with adult-onset type 2 diabetes; how these findings influenced the care and treatment recommendations for youth with type 2 diabetes; and how the many lessons from these studies, in turn, highlight remaining unanswered questions. We feature recent findings regarding long-term follow-up of diabetes complications in these youth, and how they differ from youth with type 1 diabetes. Finally, we conclude with an overview of emerging studies and topics in type 2 diabetes research that have potential to inform effective preventive action strategies.

Indexed as

Diabetes Mellitus, Type 2AdolescentAdultAge of OnsetChildHumans

Identifiers

PMID40272281
PMCPMC12178624

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.